Can Merck Keep Growing?

With shares of Merck (NYSE:MRK) trading around $44, is MRK an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let’s analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

C = Catalyst for a Stock’s Movement

Merck provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. With an increasing amount of people living longer, healthcare is becoming a main concern for many. Merck is a giant in this industry so they are well-positioned to capitalize on this movement. Look for Merck to continue its dominance as a provider of healthcare solutions worldwide.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

T = Technicals on the Stock Chart are Mixed

Merck is a stock that has been whipsawing around over the last decade. The stock has seen periods of euphoric rises that are often followed by periods of steep declines. Since the fierce stock market decline in 2008, Merck stock has risen on higher highs and higher lows, like most stocks. This uptrend should remain in tact until the stock hits a zone of significant selling pressure, more than likely near the $60 price area.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Premium Newsletters

Stock Investor Cheat Sheet

Stock Investor Cheat Sheet®

The ultimate Cheat Sheet for finding winning stock picks.
Learn More

Gold & Silver Newsletter

Gold & Silver

Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
Learn More

Commodities Premium Newsletter

Commodities Premium

There's always a bull market in some sector! Find the best opportunities in commodities.
Learn more

ETF Investing

ETF Investing

At last, a trading system that buys the right ETFs at the right time, time after time!
Learn more

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business